Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia

Leuk Res. 2010 Jul;34(7):e176-7. doi: 10.1016/j.leukres.2010.01.025. Epub 2010 Feb 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Biomarkers, Tumor
  • Drug Resistance, Neoplasm
  • Female
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / blood
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imatinib Mesylate
  • Incidental Findings
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Middle Aged
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / therapeutic use*
  • RNA, Messenger / blood
  • RNA, Neoplasm / blood
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Biomarkers, Tumor
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • RNA, Messenger
  • RNA, Neoplasm
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl